Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TELA Bio (TELA) Receivables (2018 - 2026)

TELA Bio has reported Receivables over the past 8 years, most recently at $10.3 million for Q4 2025.

  • For Q4 2025, Receivables rose 2.47% year-over-year to $10.3 million; the TTM value through Dec 2025 reached $10.3 million, up 2.47%, while the annual FY2025 figure was $10.3 million, 2.47% up from the prior year.
  • Receivables for Q4 2025 was $10.3 million at TELA Bio, down from $11.3 million in the prior quarter.
  • Over five years, Receivables peaked at $11.3 million in Q3 2025 and troughed at $2.8 million in Q1 2021.
  • A 5-year average of $7.6 million and a median of $8.0 million in 2023 define the central range for Receivables.
  • Biggest five-year swings in Receivables: skyrocketed 59.19% in 2022 and later rose 0.46% in 2025.
  • Year by year, Receivables stood at $4.2 million in 2021, then skyrocketed by 56.38% to $6.6 million in 2022, then soared by 47.06% to $9.7 million in 2023, then rose by 3.71% to $10.1 million in 2024, then rose by 2.47% to $10.3 million in 2025.
  • Business Quant data shows Receivables for TELA at $10.3 million in Q4 2025, $11.3 million in Q3 2025, and $11.2 million in Q2 2025.